The BioPharm Brief: AI, T-Cell Engagers, and Longevity Research

Sep 15, 08:08 PM
Headliner
Share
Subscribe

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, technology, and drug development. Today’s update looks at next-generation T-cell engagers in multiple myeloma, artificial intelligence in longevity research, and the digital infrastructure increasingly underpinning modern biopharma.

Share
Subscribe
Next
The BioPharm Brief: Survival, Gene Editing, and Skin Cancer
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief